EQS-News: Gerresheimer, Stevanato Group and SCHOTT Pharma join strategic ‘Alliance for RTU’

Gerresheimer, Stevanato Group and SCHOTT Pharma have formed a strategic “Alliance for RTU-”

• Marktakzeptanz von “Ready-to-Use”-Primärverpackungen schreitet vooran
• Verbesserung der Betriebseffizienz in pharmazeutischen Herstellungsprozessen
• Patient care due to highly sterile primary packaging

Düsseldorf, September 26, 2024. The Gerresheimer AG (MDAX: GXI), innovative systems and life support provider and global partner for the pharmaceutical, biotech and cosmetics industries, the Stevanato Group SpA (NYSE: STVN) and the SCHOTT Pharma AG & Co KGaA ( MDAX: 1SXP) has a strategic Industry Alliance (“Alliance for RTU”) geschlossen, a markttakzeptanz of Ready-to-Use (RTU)-Fläschchen und -Karpulen zu fördern.

The soul of the “Alliance for RTU” consists of pharmaceutical companies, CMOs and CDMOs Expertise and technical know-how on very high sterile primary packaging, continuous packaging materials and cartridges, so that the packaging can be customized and the shape of RTU configurations can be adapted to bulk packaging.

Lower risks and lower costs

Traditional Fill & Finish processes carry various operational risks and result in higher efficiency. By introducing a turnkey (RTU) industrial plant, pharmaceutical companies and CMOs can take small risks, higher flexibility and efficiency leading to lower profits. The RTU technology can be developed, processes will be rationalized, products will be produced and the total cost of ownership (TCO) will be paid, which will increase the control risks and the implementation of EU-GMP Annex 1 will be completed.

Pharmaceutical companies, CMOs and CDMOs, using ready-made primary packaging, can make high-quality products profitable, minimize the production of glassware and increase the shelf life of the drug while protecting their entire life cycle.

Open Expert Platform for the RTU Industry Standard

Darüber could make the market investments in fortskritliche aseptic Abfilltechnologien. Basis is the rising demand for injizierbaaren Arzneimitteln and the regulatory pressure on the implementation of safety standards. In this context, the “Alliance for RTU” will become an expert platform that also offends other actors in the industry. If you help the resellers, you can make the right choice from RTU sales and products to inform, a study of the efficient extraction systems that are needed to replace, which are carried out in the future – from clinical applications to your knitting Merziellen Utzung.

“When Industry is about the transition to RTU flash and carcasses, we are best prepared,” says Lukas Burkhardt, Member of the Board of Gerresheimer AG. “With the recent Fortschritung, the RTU declaration is now an outsourced technology, the employee of the company can no longer work with efficiency, costs and market information from all over the world.”

„RTU-Fläschchen und -Karpulen set a bedeuten Fortschritt in der Productqualität dar and bieten more Zuverlässigkeit and Effizienz in pharmaceutical Prozessen. This Allianz is not even deutlicher of the machine, but the RTU standards in the joint industry are a safe and effective preparation of medications for patient well-being,” says Franco Stevanato, CEO of the Stevanato Group.

“The presentation of ready-to-use packaging and cartridges reflects a collective trend in the industry wider, to improve qualitatively and efficiently in aseptic filling processes. This Alliance said that it is a shame to further develop capacities and to undermine the market trend”, says Andreas Reisse, CEO of SCHOTT Pharma. “Ready-to-use solutions can reduce complexity and strengthen modern pharmaceutical production.”

The “Alliance for RTU” will be officially opened on October 8, 2024 at the CPHI in Mailland.

For more information, visit www.alliance-for-rtu.com.

About Gerresheimer
Gerresheimer is an innovative system and solution provider and global partner for the pharmaceutical, biotech and cosmetics industries. The company offers a comprehensive portfolio of pharmaceutical managed solutions, drug delivery systems and medical products that provide solutions for the healthcare industry. The product range is a digital product offering for therapies, drug pumps, sprays, pens, auto-injectors and inhalers for bottles, ampoules, tablet holders, tropflasks, other bottles and more. Gerresheimer ensures the right treatment and a complete treatment of medicines and patients. With 35 production plants in 16 states in Europe, America and Asia, Gerresheimer has a global presence and produces locally for regional markets. With around 12,000 employees, the company will achieve an increase of around € 2 billion in 2023. Die Gerresheimer AG is listed in MDAX der Frankfurter Wertpaperbörse (ISIN: DE000A0LD6E6).
www.gerresheimer.com

About the Stevanato Group
Founded in 1949, the Stevanato Group is a prosperous enterprise of the pharmaceutical, biotechnological and bioscience industry in the areas of Drug Containment, Drug Delivery and Diagnostics. The Group has an integrated, complete portfolio of products, products and services, which are the origins of knowledge about the gesamten lebenszyklus of Arzneimitteln in je der Detwicklungs-, clinical and commercial phase. The core competencies of the Stevanato Group in the research of the search for and the solution of problems, their commitment to technical innovations and their technical strategies are one of the best ways to make their investments, and their technical innovations.
www.stevanatogroup.com

About SCHOTT Pharma
Health is separated. SCHOTT Pharma managed to erase the financing of loans, the medicines for the human in the field of health and loneliness by using it. The portfolio is equipped with an optimal storage and processing system for medicines, and gives a huge amount of spritzes made of glass and polymer, cartridges, bottles and ampoules. Over 4,600 people from over 60 nations work at SCHOTT Pharma every day, thus making a contribution to global health care. With 16 modern works in Europe, North and South America, Asia is the company in all the pharmaceutical markets. There are more than 1,000 own patents, technologies and a modern R&D center active in the Swiss innovation center of the world. SCHOTT Pharma AG & Co. KGaA is located in Hauptsitz in Mainz and is listed in MDAX in the Frankfurter Wertpapierbörse. It is a division of SCHOTT AG, a division of the Carl-Zeiss-Stiftung. At that time, it is so that SCHOTT Pharma is a product for the company and the health care sector that will be climate-neutral in 2030. The 30 pharmaceutical companies have received a drug and drug intake of 1,800 with SCHOTT Pharma. I have earned a sum of 899 million euros in 2023.
www.schott-pharma.com

Contacts

Gerresheimer AG

Median
Jutta Lorberg
Phone: +49 211 6181 264
(email address)

Investor Relations
Guido Pickert
Phone: +49 152 900 14145
(email address)

SCHOTT Pharmaceuticals

Median
Joana Kornblum
Phone: +49 151 29223552
(email address)

Investor Relations
Jasko Terzic, CFA
(email address)

Stevanato Group

Median
(email address)
Cassie Gonzalez
(email address)

Investor Relations
Lisa Miles
(email address)